Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Peptides

• Publication date

  2008-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.PEPTIDES.2007.08.013PMID 17900760
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans.

  2007cited by this paper
• Cardiovascular effects of native and non-native urotensin II and urotensin II-related peptide on rat and salmon hearts.

  2006cited by this paper
• Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation.

  2006influential reference
• Abstract 3000: Increased Human Urotensin II Levels are Correlated With Carotid Atherosclerosis in Essential Hypertension

  2006cited by this paper
• Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers.

  2006cited by this paper
• Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal disease.

  2006cited by this paper
• Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease.

  2006cited by this paper
• Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch.

  2005cited by this paper
• Expression of urotensin-II in human coronary atherosclerosis.

  2005cited by this paper
• Cardiac actions of central but not peripheral urotensin II are prevented by beta-adrenoceptor blockade.

  2005cited by this paper
• Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats.

  2005cited by this paper
• From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function.

  2004cited by this paper
• Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System

  2004cited by this paper
• Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat.

  2004cited by this paper
• The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease.

  2004cited by this paper
• Urotensin II in the cardiovascular system.

  2004cited by this paper
• Effects of rat urotensin II on coronary flow and myocardial eNOS protein expression in isolated rat heart.

  2004cited by this paper
• Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile.

  2004cited by this paper
• Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors.

  2004cited by this paper
• Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart.

  2004cited by this paper
• Heterodimers and family-B GPCRs: RAMPs, CGRP and adrenomedullin.

  2004cited by this paper
• Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta.

  2004cited by this paper
• Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy.

  2004cited by this paper
• Structure-activity relationships and structural conformation of a novel urotensin II-related peptide.

  2004influential reference
• Direct Actions of Urotensin II on the Heart: Implications for Cardiac Fibrosis and Hypertrophy

  2003cited by this paper
• Effect of human urotensin-II infusion on hemodynamics and cardiac function.

  2003influential reference
• Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain.

  2003cited by this paper
• Urotensin II Acts Centrally to Increase Epinephrine and ACTH Release and Cause Potent Inotropic and Chronotropic Actions

  2003cited by this paper
• [Effects of urotensin II on isolated rat hearts under normal perfusion and ischemia reperfusion].

  2003cited by this paper
• Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.

  2003cited by this paper
• Congestive heart failure and expression of myocardial urotensin II.

  2002cited by this paper
• Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure.

  2002cited by this paper
• Plasma urotensin II in heart failure.

  2002cited by this paper
• Familial clustering of (mostly) HCV-related cirrhosis. A case-control study.

  2002cited by this paper
• Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension.

  2001cited by this paper
• Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats

  2001cited by this paper
• Synergistic Effect of Urotensin II With Mildly Oxidized LDL on DNA Synthesis in Vascular Smooth Muscle Cells

  2001cited by this paper
• Role of urotensin II in patients on dialysis.

  2001cited by this paper
• Deconvolution Analysis of Cardiac Natriuretic Peptides During Acute Volume Overload

  2000cited by this paper
• Human urotensin‐II is an endothelium‐dependent vasodilator in rat small arteries

  2000cited by this paper
• Human urotensin II mediates vasoconstriction via an increase in inositol phosphates.

  2000cited by this paper
• Differential vasoconstrictor activity of human urotensin‐II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey

  2000influential reference
• Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries.

  2000cited by this paper
• Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14

  1999influential reference
• Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients.

  1976cited by this paper

• EXPLORATION OF THE UROCONTRIN A SCAFFOLD YIELDS NEW UROTENSINERGIC SYSTEM ALLOSTERIC MODULATOR AND COMPETITIVE ANTAGONISTS.

  2023cites this paper
• Urotensin II Receptor Modulation with 1,3,4-Benzotriazepin-2-one Tetrapeptide Mimics.

  2023cites this paper
• Time-Course Transcriptional and Chromatin Accessibility Profiling Reveals Genes Associated With Asymmetrical Gonadal Development in Chicken Embryos

  2022cites this paper
• Targeting the Urotensin II/UT G Protein-Coupled Receptor to Counteract Angiogenesis and Mesenchymal Hypoxia/Necrosis in Glioblastoma

  2021cites this paper
• Identifying Circulating Urotensin II and Urotensin II-Related Peptide-Generating Enzymes in the Human Plasma Fraction Cohn IV-4.

  2021cites this paper
• Relationship Between Myocardial Injury and Expression of PGC-1α and Its Coactivators in Chronic Keshan Disease

  2021cites this paper
• Lipidated peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as biased allosteric ligands

  2021cites this paper
• Membrane-tethered peptides derived from intracellular loops 2 and 3 of the urotensin II receptor act as allosteric biased ligands

  2020cites this paper
• Insights into the Molecular Determinants Involved in Urocontrin and Urocontrin A Action.

  2020cites this paper
• UTS2B defines a novel enteroendocrine cell population and regulates GLP-1 secretion through SSTR5 in male mice.

  2019cites this paper
• The Endocrine Kidney

  2019cites this paper
• Regulation of the cortisol stress response during and after exposure to chronic and severe hypoxia in crucian carp (Carassius carassius) and goldfish (Carassius auratus)

  2019cites this paper
• Towards Targeting the Urotensinergic System: Overview and Challenges.

  2019cites this paper
• Genetic polymorphisms of UTS2 rs2890565 Ser89Asn in coronary heart disease and myocardial infarction in Chinese population.

  2018cites this paper
• Discovery of New Allosteric Modulators of the Urotensinergic System through Substitution of the Urotensin II-Related Peptide (URP) Phenylalanine Residue.

  2018cites this paper
• Plasma urotensin II levels in primary Raynaud's phenomenon and systemic sclerosis

  2017cites this paper
• Synthèse en phase solide de pyrrolo[3,2-e][1,4]diazépin-2-ones modulateurs du système urotensinergétique

  2017cites this paper
• Insight into the role of urotensin II‐related peptide tyrosine residue in UT activation

  2017cites this paper
• The Urotensin II System and Carotid Atherosclerosis: A Role in Vascular Calcification

  2016cites this paper
• Urotensin-ⅡReceptor Antagonist SB-710411 Protects Rat Heart against Ischemia-Reperfusion Injury via RhoA/ROCK Pathway

  2016cites this paper
• De Novo Conception of Small Molecule Modulators Based on Endogenous Peptide Ligands: Pyrrolodiazepin-2-one γ-Turn Mimics That Differentially Modulate Urotensin II Receptor-Mediated Vasoconstriction ex Vivo.

  2015cites this paper
• International Union of Basic and Clinical Pharmacology. XCII. Urotensin II, Urotensin II–Related Peptide, and Their Receptor: From Structure to Function

  2015cites this paper
• Urotensin II Protects Cardiomyocytes from Apoptosis Induced by Oxidative Stress through the CSE/H2S Pathway

  2015cites this paper
• Circulating levels of the vasoactive peptide urotensin II in patients with acute coronary syndrome and stable coronary artery disease.

  2014cites this paper
• Concordant localization of functional urotensin II and urotensin II‐related peptide binding sites in the rat brain: Atypical occurrence close to the fourth ventricle

  2014cites this paper
• Urotensin II promotes vagal‐mediated bradycardia by activating cardiac‐projecting parasympathetic neurons of nucleus ambiguus

  2014cites this paper
• Angiotensin II and the JNK pathway mediate urotensin II expression in response to hypoxia in rat cardiomyocytes.

  2014cites this paper
• Effects of urotensin II on intracellular pH regulation in cultured human internal mammary artery smooth muscle cells.

  2014cites this paper
• Development and pharmacological characterization of conformationally constrained urotensin II-related peptide agonists.

  2013cites this paper
• Discovery of new antagonists aimed at discriminating UII and URP‐mediated biological activities: insight into UII and URP receptor activation

  2013influential citation
• Update on the urotensinergic system: new trends in receptor localization, activation, and drug design

  2012influential citation
• Biochemical and pharmacological characterization of nuclear urotensin‐II binding sites in rat heart

  2012influential citation
• Urotensin II prevents cardiomyocyte apoptosis induced by doxorubicin via Akt and ERK.

  2012cites this paper
• Urotensin II protects ischemic reperfusion injury of hearts through ROS and antioxidant pathway.

  2012cites this paper
• Urocontrin, a novel UT receptor ligand with a unique pharmacological profile.

  2012cites this paper
• EGFR trans-activation by urotensin II receptor is mediated by β-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy

  2011cites this paper
• Increased urotensin‐II activity in patients with Raynaud’s phenomenon and systemic lupus erythematosus

  2011cites this paper
• Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats.

  2010cites this paper
• Urotensin II, from fish to human

  2010cites this paper
• Urotensin II receptor and acetylcholine release from mouse cervical spinal cord nerve terminals.

  2010cites this paper
• Role of Novel Biomarkers in Chronic Kidney Disease: Urotensin II

  2010cites this paper
• Urotensin II stimulates high frequency-induced ANP secretion via PLC-PI 3K-PKC pathway.

  2010cites this paper
• Plasma urotensin II as a marker for severity of rheumatic valve disease.

  2009cites this paper
• Research Report 2008

  2009cites this paper
• Urotensin II and urotensin II-related peptide activate somatostatin receptor subtypes 2 and 5.

  2008cites this paper
• Urotensin II: a cardiovascular and renal update

  2008cites this paper